CATAPRES dosage and administration: Difference between revisions
No edit summary |
|||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{Ergotamine}} | ||
{{CMG}}; {{AE}} {{PB}} | {{CMG}}; {{AE}} {{PB}} | ||
'''''For patient information, click [[ | '''''For patient information, click [[Ergotamine (patient information)|here]]'''''. | ||
==Dosage and Administration== | ==Dosage and Administration== | ||
| Line 10: | Line 9: | ||
===Adults=== | ===Adults=== | ||
The dose of Catapres® ( | The dose of Catapres® (Ergotamine hydrochloride, USP) tablets must be adjusted according to the patient's individual blood pressure response. The following is a general guide to its administration. | ||
===Initial Dose=== | ===Initial Dose=== | ||
| Line 22: | Line 21: | ||
===Renal Impairment=== | ===Renal Impairment=== | ||
Patients with renal impairment may benefit from a lower initial dose. Patients should be carefully monitored. Since only a minimal amount of | Patients with renal impairment may benefit from a lower initial dose. Patients should be carefully monitored. Since only a minimal amount of Ergotamine is removed during routine hemodialysis, there is no need to give supplemental Ergotamine following dialysis.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = CATAPRES (Ergotamine HYDROCHLORIDE) TABLET [BOEHRINGER INGELHEIM PHARMACEUTICALS INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d7f569dc-6bed-42dc-9bec-940a9e6b090d | publisher = | date = | accessdate = 5 February 2014 }}</ref> | ||
==References== | ==References== | ||
Revision as of 01:58, 11 February 2014
| Ergotamine |
|---|
| ERGOMAR (ergotamine tartrate) tablet® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Dosage Forms and Strengths |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| Clinical Studies |
| How Supplied/Storage and Handling |
| Patient Counseling Information |
| Labels and Packages |
| Medihaler ergotamine (ergotamine tartrate) aerosol, metered® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Dosage Forms and Strengths |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| Clinical Studies |
| How Supplied/Storage and Handling |
| Patient Counseling Information |
| Labels and Packages |
| Clinical Trials on Medihaler ergotamine (ergotamine tartrate) aerosol, metered |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]
For patient information, click here.
Dosage and Administration
Adults
The dose of Catapres® (Ergotamine hydrochloride, USP) tablets must be adjusted according to the patient's individual blood pressure response. The following is a general guide to its administration.
Initial Dose
0.1 mg tablet twice daily (morning and bedtime). Elderly patients may benefit from a lower initial dose.
Maintenance Dose
Further increments of 0.1 mg per day may be made at weekly intervals if necessary until the desired response is achieved. Taking the larger portion of the oral daily dose at bedtime may minimize transient adjustment effects of dry mouth and drowsiness. The therapeutic doses most commonly employed have ranged from 0.2 mg to 0.6 mg per day given in divided doses. Studies have indicated that 2.4 mg is the maximum effective daily dose, but doses as high as this have rarely been employed.
Renal Impairment
Patients with renal impairment may benefit from a lower initial dose. Patients should be carefully monitored. Since only a minimal amount of Ergotamine is removed during routine hemodialysis, there is no need to give supplemental Ergotamine following dialysis.[1]
References
- ↑ "CATAPRES (Ergotamine HYDROCHLORIDE) TABLET [BOEHRINGER INGELHEIM PHARMACEUTICALS INC.]". Retrieved 5 February 2014.